Q1 Earnings Forecast for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Leerink Partnrs lowered their Q1 2026 earnings per share estimates for Illumina in a research report issued on Monday, October 13th. Leerink Partnrs analyst P. Souda now expects that the life sciences company will post earnings per share of $1.05 for the quarter, down from their prior estimate of $1.09. The consensus estimate for Illumina’s current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for Illumina’s Q4 2026 earnings at $1.43 EPS.

Other equities research analysts have also recently issued reports about the stock. Canaccord Genuity Group lifted their price objective on shares of Illumina from $99.00 to $105.00 and gave the company a “hold” rating in a research note on Friday, August 1st. Wall Street Zen cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Daiwa America cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 12th. Citigroup cut shares of Illumina from a “hold” rating to a “strong sell” rating and cut their price objective for the company from $85.00 to $80.00 in a research note on Wednesday, July 9th. Finally, Morgan Stanley lifted their price objective on shares of Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, August 4th. Five investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Illumina currently has a consensus rating of “Hold” and a consensus price target of $115.25.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $95.91 on Thursday. Illumina has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The firm’s 50-day simple moving average is $98.11 and its 200 day simple moving average is $90.56. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The stock has a market cap of $14.74 billion, a P/E ratio of 12.14, a P/E/G ratio of 2.24 and a beta of 1.40.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period last year, the business posted $0.36 earnings per share. The firm’s quarterly revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS.

Hedge Funds Weigh In On Illumina

A number of institutional investors have recently bought and sold shares of the stock. CWM LLC grew its stake in Illumina by 43.9% during the 3rd quarter. CWM LLC now owns 110,375 shares of the life sciences company’s stock valued at $10,482,000 after acquiring an additional 33,664 shares in the last quarter. Pacer Advisors Inc. purchased a new position in Illumina during the 3rd quarter valued at about $61,663,000. Swedbank AB grew its stake in Illumina by 57.6% during the 3rd quarter. Swedbank AB now owns 825,491 shares of the life sciences company’s stock valued at $78,397,000 after acquiring an additional 301,806 shares in the last quarter. Optas LLC purchased a new position in Illumina during the 3rd quarter valued at about $215,000. Finally, Farther Finance Advisors LLC grew its stake in Illumina by 12.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,824 shares of the life sciences company’s stock valued at $268,000 after acquiring an additional 303 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.